Lactate Transporter SLC16A3 (MCT4) as an Onco-Immunological Biomarker Associating Tumor Microenvironment and Immune Responses in Lung Cancer

Qingsong Tao; Xin Li; Ting Zhu; Xiaoqin Ge; Shengping Gong; Jianxin Guo; Ruishuang Ma

doi:10.2147/IJGM.S353592

Lactate Transporter SLC16A3 (MCT4) as an Onco-Immunological Biomarker Associating Tumor Microenvironment and Immune Responses in Lung Cancer

Int J Gen Med. 2022 Apr 27:15:4465-4474. doi: 10.2147/IJGM.S353592. eCollection 2022.

Authors

Qingsong Tao^#¹, Xin Li^#², Ting Zhu¹, Xiaoqin Ge¹, Shengping Gong¹, Jianxin Guo¹, Ruishuang Ma^{1

3}

Affiliations

¹ Department of Radiotherapy and Chemotherapy, Ningbo First Hospital, Ningbo, People's Republic of China.
² Department of Respiratory Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
³ Central Laboratory of the Medical Research Center, Ningbo First Hospital, Ningbo, People's Republic of China.

^# Contributed equally.

Abstract

Purpose: Lactate, a marker of tumor metabolic reprogramming, maintains the acidic microenvironment and also affects the metabolism and function of immune cells. SLC16A3 is responsible for the extracellular transport of lactate, which is a key component of glycolysis. However, the role of SLC16A3 in immune infiltration and immunosuppression of lung cancer is largely unknown. Our study explored the therapeutic and prognostic value of SLC16A3 in predicting immune infiltration and immune checkpoint efficacy of lung cancer.

Methods: SLC16A3 expression was evaluated with TCGA database. Kaplan-Meier analysis was performed for survival rates. GO and KEEG enrichment was conducted to determine predictive signaling pathways. We utilized TIMER and CIBERSORT to analyze the correlation between SLC16A3 and immunocyte infiltration as well as immune checkpoint. Interleukin and HIF-1a expression was measured with ELISA kit and flow cytometry separately.

Results: In comparison with normal tissues, SLC16A3 expression was significantly upregulated in both lung adenocarcinoma (LUAD) and squamous carcinoma (LUSC), which was closely related to poor prognosis. GO analysis indicated that SLC16A3 involved in different signal pathways in LUAD and LUSC and linked to HIF-1 signaling in LUAD. High SLC16A3 was correlated with immunosuppressive cells (Treg, Th2 and iDC), immune checkpoint (PD1, PD-L1, PVR, Tim-3, ITGAM) and immunosuppressive factors (foxp3, TGF-β) in LUAD not LUSC. Furthermore, SLC16A3 was identified to tightly interact with IL-8 which may induce microenvironment immune tolerance. Based on the clinical prediction, we performed experiments with LUAD A549 cells and showed reduced IL-8 and HIF-1a when treated with SLC16A3 knockdown. HIF-1a stimulation by dimethyloxalylglycine (DMOG) could restore IL-8 secretion in SLC16A3 downregulated cells.

Conclusion: Taken together, our results suggest that SLC16A3 contributes to a worse prognosis in lung cancer and may play an important role in immune microenvironment and evasion through HIF-1a-IL8 axis, which could be a novel therapeutic target for immunotherapy in lung cancer.

Keywords: IL-8; SLC16A3 (MCT4); bioinformatics analysis; immune evasion; lung cancer.